Eva Kováčová is CEO of Slovak company Glycanostics that has developed early stage cancer diagnostic tests for detection of 11 types of tumours - Giasay. The tests are based on the analysis of glycans in blood. The company currently launches its prostate cancer test in Slovakia, to be followed by the breast cancer test at the end of 2023. Towards the end of 2023 they plan expansion to German market, to be followed by pre-launch activities in the USA. In addition to that Glycanostics starts the research work on lung and pancreatic cancer tests. Glycanostics is beneficent of highly prestigious European grants such as ERC, EIC Accelerator and EIC Transition grant. Prior to that she worked more than 18 years for some of the largest pharmaceutical companies in M&A, as well as finance leadership. She was member of the team that secured signing of the deal between GSK and Novartis in the value of 30bn EUR, she led the integration project in EMEA and LATAM to create joint venture between GSK and Novartis and later between GSK and Pfizer in the value of 10bn EUR (today known as Haleon). She was also in charge of the carve out process of LifeScan division from Johnson & Johnson in EMEA in the value of 2bn EUR.